Acute ST-segment elevation myocardial infarction: A rare initial presentation of previously undiagnosed essential thrombocythemia

References

• Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916–919
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466
   PubMed Web of Science ®Google Scholar
• Mizuta E, Takeda S, Sasaki N, Miake J, Hamada T, Shimoyama M, Tajima F, Igawa O, Shigemasa C, Hisatome I. Acute myocardial infarction in a patient with essential thrombocythemia: Successful treatment with percutaneous transluminal coronary recanalization. Circ J 2005; 69: 1000–1002
   PubMed Web of Science ®Google Scholar
• Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med 1998; 244: 49–53
   PubMed Web of Science ®Google Scholar
• Raymond R, Lynch J, Underwood D, Leatherman J, Razavi M. Myocardial infarction and normal coronary arteriography: A 10 year clinical and risk analysis of 74 patients. J Am Coll Cardiol 1988; 11: 471–477
   PubMed Web of Science ®Google Scholar
• Da Costa A, Isaaz K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram; a 3-year follow-up study of 91 patients. Eur Heart J 2001; 22: 1459–1465
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976–1995. J Hematol 1999; 61: 10–15
   PubMed Web of Science ®Google Scholar
• Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia Vera and essential thrombocythemia. Blood 2006; 107: 4214–4222
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556–562
   PubMed Web of Science ®Google Scholar
• Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556
   PubMed Web of Science ®Google Scholar
• Gül C, Kürüm T, Demir M, Ozbay G, Vural O, Iqbal O, Fareed J. Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor. Clin Appl Thromb Hemost 2004; 10: 77–79
   PubMed Web of Science ®Google Scholar
• Daya SK, Gowda RM, Landis WA, Khan IA. Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology 2004; 55: 319–323
   Google Scholar
• Watanabe T, Fujinaga H, Ikeda Y, Higashi T, Murakami M, Kawahara K, Hayashi I, Niki T, Shigekiyo T, Wakatsuki T. Acute myocardial infarction in a patient with essential thrombocythemia who underwent successful stenting: A case report. Angiology 2005; 56: 771–774
   PubMed Web of Science ®Google Scholar
• Bildirici U, Celikyurt U, Ural E. Essential thrombocythemia: A case of acute ST-segment elevation myocardial infarction in a young female. Clin Cardiol 2009; 32: 104–105
   PubMed Web of Science ®Google Scholar
• Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 2006; 32: 372–380
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. N Engl J Med 1995; 332: 1132–1136
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372–380
   PubMed Web of Science ®Google Scholar
• Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56: 168–172
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945–1953
   PubMed Web of Science ®Google Scholar
• Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective. Ann Intern Med 1997; 127: 895–903
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infraction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–917
   PubMed Web of Science ®Google Scholar
• Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implication for venous thromboembolism screening. JAMA 1997; 277: 1305–1307
   Google Scholar